Pricing Log in Create free account

Entrada Therapeutics, Inc. (TRDA) vs Upstream Bio, Inc. (UPB)

Entrada Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Entrada Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($186.1M and $184.6M). Upstream Bio, Inc. grew revenue faster over the last twelve months: 16.0% against −94.1%. Entrada Therapeutics, Inc. has the higher net margin (−3,537.7% vs −4,955.7%) and the higher return on invested capital (−1,060.2% vs −1,100.9%). Across the 16 metrics below, Entrada Therapeutics, Inc. leads on 10 and Upstream Bio, Inc. on 6.

Valuation

Metric TRDA UPB Biotechnology median
P/E n/m n/m 8.50
P/S 39.28 47.69 9.71
P/B 0.79 0.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.22 0.65 0.64
EV/Sales (8.31) (35.05) 9.21
Earnings yield (90.83%) (105.07%) (33.15%)
Free cash flow yield (72.98%) (90.76%) (25.50%)

Profitability

Metric TRDA UPB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (3,767.07%) (5,382.65%) 0.00%
Net margin (3,537.73%) (4,955.67%) 0.00%
Free cash flow margin (2,867.07%) (4,317.42%) 0.00%
Return on equity (54.09%) (46.05%) (56.36%)
Return on assets (44.35%) (44.61%) (48.04%)
Return on invested capital (1,060.24%) (1,100.93%) 0.00%

Growth

Metric TRDA UPB Biotechnology median
Revenue growth (TTM) (94.10%) 15.98% 6.02%
EPS growth (last fiscal year) (306.55%) 52.33% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric TRDA UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.89 27.99 4.72
Net debt to EBITDA 1.88 2.11 0.96

Dividend

Metric TRDA UPB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric TRDA UPB Biotechnology median
Market cap 186.12m 184.58m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack